Abstract Recent advances in the treatment of prostate cancer have resulted in improved outcomes, including longer survival, but new options are needed for treating patients with castration-resistant disease, particularly in the presence of bone metastasis. Data from preclinical models and clinical biomarker studies indicate that antiangiogenic agents should be a promising treatment for this patient population, and multiple agents in this class have demonstrated activity in early-stage clinical trials. Pivotal trials in prostate cancer with agents targeting vascular endothelial growth factor (VEGF) signalling have resulted in signifi cant improvements in tumour response and progression-free survival. However, overall survival was not signifi cantly improved. Recent preclinical studies suggest that the limited impact on overall survival may result from the development of evasive resistance after inhibition of angiogenesis, possibly through upregulation of MET (hepatocyte growth factor receptor) signalling. MET plays important roles in angiogenesis, tumour cell invasion and bone metastasis, all of which are key factors in castrationresistant prostate cancer. Inhibition of both the MET and VEGF pathways may improve the effi cacy of angiogenesis inhibitors in prostate cancer.
Introduction
Prostate cancer is the most common non-cutaneous cancer in men. In 2010, an estimated 217,730 new prostate cancer cases were diagnosed in the USA, and more than 32,000 deaths were estimated to occur, making it the second-leading cause of cancer-related death in men [1] . As prostate cancer cells express androgen receptors and are initially androgen-dependent, hormonal-based therapy-also referred to as androgen deprivation therapy-is the initial treatment of choice [2] . While the disease typically responds to this therapy, nearly all patients eventually progress despite castrate levels of androgens (<50 ng/ml); at this stage the disease is known as castration-resistant prostate cancer (CRPC) [2] . Early clinical manifestations of progressive CRPC include bone metastases, rising serum prostate-specifi c antigen (PSA) levels and pain [3] . Multiple drugs have been approved for CRPC, including the chemotherapeutics docetaxel and cabazitaxel, the immunotherapeutic sipuleucel-T, and the androgen biosynthesis inhibitor abiraterone [4] . While these agents can prolong survival, the prognosis for CRPC remains poor and new therapeutic approaches are needed.
Antiangiogenic therapy in prostate cancer
Angiogenesis is essential for tumour growth and metastasis [5] [6] [7] . Antiangiogenic approaches, most of which rely on D.T. Aftab (౧) Exelixis, Inc. 210 East Grand Avenue South San Francisco, CA 94083-0511, USA e-mail: daftab@exelixis.com targeting the vascular endothelial growth factor (VEGF) signalling pathway, have emerged as important therapeutic options in treating a range of cancers, including those of the lung, colon, breast and kidney. VEGF-driven angiogenesis also appears to be a promising target in prostate cancer. Expression of VEGF is low in normal prostate tissues [8] but is upregulated in metastatic prostate cancer [8, 9] . In addition, the microvascular density of prostate tumours correlates with disease progression [10, 11] , and elevated levels of VEGF in plasma or urine correlate with advanced stage, progression and poor patient outcomes in prostate cancer [9, 12, 13] .
Based on these fi ndings, and on promising treatment responses in other tumour types, multiple antiangiogenic agents that target VEGF signalling have been studied in patients with CRPC. Improvement in tumour response and/or progression-free survival was observed with bevacizumab, sorafenib, sunitinib and cediranib in phase 2 trials in CRPC [14] [15] [16] [17] [18] [19] [20] . Similar benefi ts were observed with bevacizumab and sunitinib in phase 3 trials [21, 22] . However, statistically signifi cant improvement in overall survival was not found in the latter pivotal trials.
Similar results were obtained with several antiangiogenic agents in a variety of tumour types other than CRPC, where evidence of initial clinical benefi t, such as tumour response and delayed progression, was not accompanied by improved overall survival in pivotal trials [23, 24] . Additionally, while agents that target the VEGF signalling pathway have been clinically important in treating some tumour types, their effi cacy in many patients is transient and eventually followed by tumour growth and progression [25] [26] [27] . In glioblastoma, relapse in some patients was associated with a concerning increase in tumour invasion and multifocal spread within the brain [28, 29] . These clinical outcomes suggest that the failure to achieve enduring clinical benefi t with treatment in some trials may result from the development of resistance to antiangiogenic therapy.
Rationale for targeting MET
Experiments in mice have demonstrated that tumours are capable of developing adaptive or evasive resistance to therapies targeting the VEGF signalling pathway [23, 30, 31] . This response of tumours to therapy is characterised by a more highly invasive and metastatic phenotype, and has been described with a wide variety of agents including the small molecule tyrosine kinase inhibitors (TKIs) sunitinib, sorafenib and cediranib, antibodies that recognise and neutralise VEGF (including bevacizumab), and a VEGFR2-targeting antibody [28] [29] [30] [32] [33] [34] [35] . One potential mechanism for the development of evasive resistance to VEGF-pathway inhibition is upregulation of MET pathway signalling [36] .
MET, the receptor for hepatocyte growth factor (HGF), is a receptor tyrosine kinase that plays important roles in cell motility, proliferation and survival, and is a key factor in tumour angiogenesis, invasiveness and metastasis [37] [38] [39] . Both MET mRNA and protein levels are substantially increased by hypoxia, which can increase cell invasion and migration away from hypoxic regions after treatment with an angiogenesis inhibitor [35, 40, 41] .
Expression of HGF is increased in murine tumour models resistant to sunitinib, and systemic administration of HGF can cause resistance to sunitinib in models that are otherwise sensitive to sunitinib [42] . Likewise, combined therapy with sunitinib and a selective inhibitor of MET is signifi cantly more effi cacious than therapy with either agent alone in sunitinib-resistant murine tumour models [42] . In addition, TKIs such as cabozantinib (XL184) and foretinib (XL880; GSK1363089), which simultaneously target the MET and VEGF signalling pathways, have a profound impact on tumour vasculature and block the development of tumour invasiveness and metastasis [35, 36] . These results are consistent with a contribution of MET signalling to the development of resistance to VEGF inhibition.
In prostate cancer, growing evidence suggests that MET signalling may play an important role in promoting malignancy, even in the absence of VEGF pathway inhibition. Expression of MET is high in benign prostate tissue (largely in basal cells) and in primary and metastatic prostate carcinomas [43] [44] [45] [46] . MET expression is higher in bone metastases than in primary tumours or lymph node metastases [47, 48] . Expression of HGF is greater in prostate carcinoma than in benign prostate tissue [11, 13] , and high plasma levels of HGF in men with CRPC correlate with decreased overall survival [49] .
Data from preclinical and clinical studies suggest that HGF and MET are regulated by androgen signalling in prostatic cells. HGF expression is low in androgen-sensitive CWR22 xenograft tumours and is signifi cantly upregulated in castration-resistant variants [50] . Similarly, androgen-sensitive prostate cancer cell lines grown in the presence of androgen typically express low or undetectable levels of MET, while CRPC cell lines generally express higher levels [46, 51] . MET expression increases substantially in androgen-sensitive cells after androgen withdrawal in vitro or after castration in androgen-sensitive xenograft tumours growing in vivo [46, 51, 52] . A similar effect has been described in normal rat prostate tissue after castration [46] . These preclinical fi ndings are consistent with clinical observations that MET expression is signifi cantly greater in tumour samples from patients with CRPC than in specimens from patients who have not yet undergone androgen deprivation therapy [53] . A possible mechanism for this difference is evident in molecular studies showing that the androgen receptor directly represses expression of the gene encoding MET via inhibition of its promoter [51] . Overall, these observations indicate that MET expression is particularly high in prostate cancer bone metastases and that increased MET signalling may refl ect the emergence of castration-resistant disease.
